A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Pfizer
Pfizer
ChineseAMS
Novartis
Peking University People's Hospital
Indonesia University
University of Maryland, Baltimore
Children's Hospital of Michigan
Cytovia, Inc.
University of Kansas Medical Center
Novartis
Novartis
Fox Chase Cancer Center
Novartis
Federal University of Minas Gerais
Pfizer
PETHEMA Foundation
Sanofi